Orphazyme20.jpg

Outlook

OUTLOOK

OUTLOOK

For the full-year 2021, Orphazyme expects operating expenses of DKK 700-720 million, resulting in an expected operating loss of DKK 670-700 million. Cash position at year-end 2021 is expected to be no less than DKK 80 million . We anticipate reaching net revenues of between DKK 30 and DKK 40 million by year-end December 31, 2021. The net revenue pertains to the ATU in France.